A prospective study of pediatric and adolescent renal cell carcinoma: A report from the Children’s Oncology Group AREN0321 study

Study ID Citation

Geller JI, Cost NG, Chi YY, Tornwall B, Cajaiba M, Perlman EJ, Kim Y, Mullen EA, Glick RD, Khanna G, Daw NC, Ehrlich P, Fernandez CV, Dome JS. A prospective study of pediatric and adolescent renal cell carcinoma: A report from the Children’s Oncology Group AREN0321 study. Cancer. 2020 Dec 1;126(23):5156-5164. doi: 10.1002/cncr.33173. Epub 2020 Sep 14. PubMed PMID: 32926409; PubMed Central PMCID: PMC7717658.

Abstract

AREN0321 is the first prospective clinical study of pediatric and adolescent renal cell carcinoma (RCC). Goals included establishing epidemiological, treatment and outcome data, and confirming that completely resected pediatric RCC, including node positive disease (N1), has a favorable prognosis without adjuvant therapy. From 2006 to 2012, patients <30yr old with centrally reviewed pathology of RCC were prospectively enrolled.

Link To Publication opens in a new tab